Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11), Bloomberg Earnings reports.
Shares of Leap Therapeutics (NASDAQ LPTX) traded up $0.14 during midday trading on Tuesday, hitting $6.25. The stock had a trading volume of 118,700 shares, compared to its average volume of 23,397. Leap Therapeutics has a twelve month low of $4.90 and a twelve month high of $10.10.
Separately, Zacks Investment Research cut Leap Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.